凱萊英(06821.HK)擬40億至50億元投資建設生物醫藥研發生產一體化基地項目
格隆匯9月26日丨凱萊英(06821.HK)公吿,公司已於2022年9月26日與江蘇省泰興經濟開發區管理委員會簽署投資協議,內容關於向集團出讓位於江蘇省泰興經濟開發區內總面積約為400畝的土地及由集團投資建設“生物醫藥研發生產一體化基地項目”。
江蘇省泰興經濟開發區為省級開發區,是江蘇省沿江開發十五個重點園區之一。本項目建設內容為小分子CDMO化學原料及原料藥的研發及生產,以及拓展小分子CDMO藥物製劑、藥物研發、新技術推廣應用等項目建設,預計總投資額約為人民幣40億元至人民幣50億元,預計資金來源包括自有資金或自籌資金,具體情況將在本項目計劃落實時確定。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.